Memorial Şişli Hospital
Terapia komórkami macierzystymi w cukrzycy w Turcji kosztuje od $12,000 do $24,000, według danych Bookimed. Średni koszt wynosi $18,000. Cena zależy od ilości podanych komórek, rodzaju materiału komórkowego (np. mezenchymalne komórki macierzyste z pępowiny), liczby sesji oraz dodatkowych procedur, takich jak terapia egzosomami i ozonoterapia.
Zazwyczaj w cenę wliczone są konsultacje endokrynologa i dietetyka, rozszerzone badania krwi (HbA1c, C-peptyd, witaminy), indywidualny plan terapii, infuzje komórek macierzystych, egzosomy, zabiegi wspomagające, opieka po leczeniu oraz kontrola jakości materiału komórkowego według standardów GMP. Sprawdzać, czy wliczone są indywidualne zalecenia dotyczące diety i witamin oraz dalsze konsultacje.
Dlaczego warto wybrać Turcję do leczenia cukrzycy typu 2 za pomocą komórek macierzystych?
Skorzystaj z zaawansowanych rozwiązań w leczeniu cukrzycy typu 2 za pomocą komórek macierzystych w zaufanych klinikach .
| Turcja | Austria | Hiszpania | |
| Terapia komórkami macierzystymi przy cukrzycy | od $12,000 | od $25,000 | od $20,000 |
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Week 1-3 post-operation
Week 4-6 post-operation
Please note that the recovery timeline may vary as each case is individual.
Specjalizuje się w dziecięcych zaburzeniach endokrynologicznych – prof. Özgen koncentruje się na cukrzycy i schorzeniach związanych ze wzrostem u dzieci w szpitalach Valued Med Hub.
Dr Kilicli ma ponad 22 lata doświadczenia w medycynie wewnętrznej, specjalizując się w leczeniu cukrzycy w najlepszych tureckich szpitalach.
Stem cell treatment for diabetes mellitus involves using regenerative therapy to repair or replace damaged pancreatic cells, aiming to improve insulin production and glucose control.
Top-rated Turkish clinics for diabetes stem-cell therapy include Liv Hospital Ulus, Memorial Şişli, and Emsey Hospital, primarily located in Istanbul. These facilities hold JCI accreditation and utilize advanced mesenchymal stem cell (MSC) protocols and specialized bone marrow transplant units to manage metabolic disorders and insulin resistance.
Bookimed Expert Insight: While many clinics offer general stem-cell drips, the highest success signals come from university-affiliated centers like Biruni or specialized units like LivMedCell. These facilities produce their own cells in-house rather than outsourcing. This internal control over cell count and viability often explains the variance in patient outcomes.
Patient Consensus: Patients often report temporary improvements in A1C levels but emphasize that these treatments are not yet a permanent cure. Many advise verifying lab-verified beta-cell regeneration data and preparing for a rigorous follow-up diet to maintain any metabolic gains achieved.
Stem cell therapy for diabetes is legal and strictly regulated in Turkey by the Ministry of Health. All regenerative medicine practices must comply with Good Manufacturing Practice standards. Procedures using adult mesenchymal stem cells are permitted, while the use of embryonic stem cells remains restricted by ethical laws.
Bookimed Expert Insight: While many clinics offer intravenous injections, the most advanced results come from facilities with in-house production centers. Liv Hospital Ulus has operated a Ministry-certified regenerative medicine lab since 2014. This integration typically ensures higher cell viability compared to clinics that outsource cell processing from external labs.
Patient Consensus: Many patients report temporary benefits like reduced insulin needs for 6–12 months. However, they emphasize that legal status does not guarantee a permanent cure for Type 1 or Type 2 diabetes.
Success rates for stem cell therapy for diabetes in Turkey range from 60% for improving insulin sensitivity to 95% in specialized multidisciplinary protocols. While these figures indicate high potential for glycemic stabilization and reduced dependency, results remain variable based on patient age, disease duration, and diabetes type.
Bookimed Expert Insight: While single-doctor clinics like You Clinic claim 95% success, larger JCI-accredited institutions like Memorial Şişli Hospital focus on overall endocrine stabilization rather than direct `cures.` Comparing mid-range packages of $12,000 to premium $24,000 options reveals that higher costs usually reflect multiple mesenchymal stem cell infusions and specialized inclusions like IV exosomes.
Patient Consensus: Many patients notice significant HbA1c drops, such as move from 9.5% to 6.2%, though some find the insulin-free status lasts approximately 18 months. It is widely recommended to confirm results with pre and post treatment C-peptide tests.
Stem cells cannot currently provide a universal, permanent cure for diabetes, though recent breakthroughs show some patients achieving long-term insulin independence. In Turkey, treatments focus on regenerating insulin-producing islet cells or improving insulin sensitivity, typically offering functional remission rather than a complete biological cure.
Bookimed Expert Insight: While many seek stem cell therapy as a final solution, data from high-volume centers like Memorial Şişli Hospital suggests success is highest when combined with specialized endocrinology follow-up. Some patients reduce medication for up to 2 years, but this often stems from the synergistic effect of cell therapy and intensive lifestyle recalibration managed by the clinic’s multidisciplinary team.
Patient Consensus: Many patients describe the treatment as a helpful pause that drops insulin needs by 50%, though some warn that benefits may diminish after 6–12 months without strict maintenance.
Diabetes treatment primarily utilizes mesenchymal stem cells (MSCs) sourced from umbilical cord tissue, bone marrow, or adipose fat. These multipotent cells specialize in immunomodulation to reduce systemic inflammation. Hematopoietic stem cells (HSCs) are also employed in specific protocols to reboot the immune response in early-onset cases.
Bookimed Expert Insight: Turkish centers like Emsey Hospital leverage extensive bone marrow transplant infrastructure for advanced cell processing. While experimental iPSCs remain in Phase 1 trials globally, Turkey focuses on high-volume MSC protocols. Data shows these treatments often target Type 2 diabetes to achieve significant insulin reduction.
Patient Consensus: Many patients report a 20-50% reduction in daily insulin needs following MSC therapy. They emphasize tracking C-peptide levels and maintaining strict diets to sustain these results beyond 6 months.
Stem cell therapy results for diabetes generally last between 6 months and 2 years. Outcomes vary by diabetes type, with Type 1 patients potentially achieving insulin independence for 12 months, while Type 2 patients often see improved glucose control persisting for 12 to 24 months.
Bookimed Expert Insight: Data suggests a significant value gap between US and Turkish treatments. While US procedures average $40,000, Turkish clinics like Memorial Şişli Hospital or Liv Hospital Ulus offer specialized care for $12,000 to $24,000. This price difference allows patients to budget for necessary booster sessions every 18 months, which is often required to sustain therapeutic benefits long-term.
Patient Consensus: Many patients find that effectiveness windows typically span 6 to 24 months. Most emphasize the need to track A1C levels monthly to identify when the therapy's impact begins to wane.